XML 37 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

INVESTMENT IN EQUITY SECURITIES | 9 Months Ended
--- | ---
Sep. 30, 2025
Equity Method Investments and Joint Ventures [Abstract] |
INVESTMENT IN EQUITY SECURITIES | INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following:
| September 30, 2025 |  | December 31, 2024
Equity Method Investments: |  |  |
Goldrain | $ | 101,473 |  |  | $ | 96,667 |
BTY | — |  |  | 32,047 |
Sonmol | 7,537 |  |  | 4,712 |
Others | 5,121 |  |  | 948 |
Other Investments: |  |  |
PureCycle | 3,831 |  |  | 2,986 |
YAT | 5,337 |  |  | 5,206 |
Others | 7,049 |  |  | 3,703 |
| $ | 130,348 |  |  | $ | 146,269 |
Equity Method Investments BTY On July 28, 2025, we increased our beneficial ownership in BTY from 49% to 80%, effectively moving from equity accounting to consolidation. For additional information, see Note 17 - Acquisitions and Note 20 - Redeemable Controlling Interests. For the year to date period through July 28, 2025, prior to consolidation upon our call exercise, Aptar had purchases of $7.4 million from BTY. For the nine months ended September 30, 2024, Aptar had purchases of $8.7 million from BTY. As of July 28, 2025 and December 31, 2024, approximately $2.1 million and $2.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. Dianosic On July 23, 2025, we invested $4.1 million to acquire 21% of the equity interests in Dianosic SAS ("Dianosic"). Based in France, Dianosic's principal activity is the purchase, manufacture, research and promotion of drug delivery systems. Goldrain On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, (referred to as “Goldrain”), a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of specialty assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments On July 2, 2025, we invested approximately $3.2 million to acquire 10% of the equity interests in Yangi, a machine builder of dry molded fiber packaging manufacturing machines. In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker symbol “PCT,” At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. No shares were sold during 2024 or 2025 related to PCT. On April 26, 2024, we received $0.2 million of equity in exchange for our resource dedication for technological partnership and support. For the three and nine months ended September 30, 2025 and 2024, we recorded the following net investment gain or loss on our investment in PureCycle:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Net investment gain (loss) | $ | (161) |  |  | $ | 1,043 |  |  | $ | 845 |  |  | $ | 1,495 |
On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the nine months ended September 30, 2025 and 2024 related to these investments.

X
- Definition The entire disclosure for equity method and other investments. + References No definition available. + Details
Name: | atr_EquityMethodAndOtherInvestmentsTextBlock
Namespace Prefix: | atr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration